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Summary
Written pamphlets are an important source of infor-
mation for individuals deciding whether to undergo car-
rier testing for cystic fibrosis (CF). Adequate understand-
ing of the condition and reproductive options following
the diagnosis of a fetus with CF are critical to informed
decision making. The information given about CF and
reproductive options in 28 pamphlets about carrier test-
ing, from commercial and noncommercial organizations
in the United States and the United Kingdom, aimed at
prenatal and other populations, was assessed. The
amount of information provided about CF showed a
range of 1–37 sentences (median 6.5), with most being
relatively neutral and with a minority conveying a pos-
itive or a negative image. Positive sentences were less
common in British, U.S. commercial, and prenatal pam-
phlets. Statements about life expectancy also varied con-
siderably, both in the ages provided and in the degree
of optimism conveyed. In addition, the pamphlets varied
in the amount of information they provided about re-
productive options following the diagnosis of a fetus
with CF. Abortion was mentioned in just 15 pamphlets,
more often in the United Kingdom than in the United
States and more frequently in pamphlets from noncom-
mercial than in those from commercial organizations.
Wide variation in the descriptions of CF and the repro-
ductive options presented raises concerns about the ex-
tent to which any one pamphlet may present balanced
information. The choices about what information to in-
clude in educational materials need to be explicitly con-
sidered on the basis of the message intended to be sent.
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Introduction
Carrier testing for cystic fibrosis (CF) has been feasible
since 1989 (Kerem et al. 1989). It has not been routinely
implemented, however, in part because of concerns
about the ability to provide, in a comprehensiblemanner,
complex information to large populations (Workshop
on Population Screening for the Cystic Fibrosis Gene
1990; Statement of The American Society of Human
Genetics on Cystic Fibrosis Carrier Screening 1992).
These concerns prompted calls for empirical research,
which were met by the implementation of a number of
studies in the United States and United Kingdom to de-
termine the feasibility and acceptability of CF carrier
testing (Wilfond and Nolan 1993).
Several of these studies found that both the perceived
nature of the disease and attitudes toward termination
played a primary role in whether the test was taken. For
example, Loader et al. (1996) found that, in pregnant
women who choose not to be tested, 32% said that it
was because they would not consider terminating a preg-
nancy because of CF, whereas, in those who accepted
testing, 28% stated that the reason was to avoid having
a child with CF. Similarly, Clayton et al. (1996) found
that, for 70% of individuals from a general population
study, abortion would be an “important” or “very im-
portant” consideration in deciding whether to be tested.
Recently, the NIH Consensus Development Confer-
ence for Genetic Testing for Cystic Fibrosis reviewed the
data from these studies and recommended that genetic
testing for CF should include “balanced information to
afford individuals the opportunity to make autonomous
decisions” (Statement of the Consensus Development
Conference on Genetic Testing for Cystic Fibrosis 1997,
p. 25). The statement concluded that balanced infor-
mation must contain descriptions of CF, including in-
formation on both the range of severity of the condition
and improvements in survival rates for individuals with
CF, as well as information about reproductive options,
including adoption, use of artificial reproductive mo-
dalities, and continuation or termination of pregnancy.
The statement’s emphasis on informed, autonomous de-
cision making is consistent with previous recommen-
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Table 1
Ratings of Sample Descriptive Statements about CF
Neutral Positive Negative
This lifelong illness
usually gets more
severe with age
and can affect
both males and
females.
People are living
longer than ever be-
fore as researchers
are continuing to
find new treatments.
If they live long
enough, they will
probably need a
heart and lung
transplant.
Lung infections are
treated with anti-
biotics but after
many years the
infections may
resist treatment.
People with CF may
use inhalers that
ease breathing, and
have chest physical
therapy at least once
a day to help re-
move mucus from
their lungs.
The sputum is so
thick that the child
cannot cough
properly and devel-
ops lung infections
which cause pro-
gressive lung
damage.
Not all children are
affected in the
same way.
Children with CF at-
tend regular schools,
and can go to col-
lege, work and get
married.
Medical bills and re-
sentment from
other children may
cause stress or
other worry.
dations about the ethical use of genetic testing (Presi-
dent’s Commission for the Study of Ethical Problems in
Medicine and Biomedical and Behavioral Research
1983; Andrews et al. 1994; Holtzman and Watson
1997).
Because all of the CF studies provided written infor-
mation to facilitate informed decision making, the aim
of the present study is to describe the amount and type
of information provided to those undergoing testing, in
order to determine the extent to which the information
meets the criteria for balanced information that are set
by the NIH Consensus Development Conference. Pam-
phlets from noncommercial (primarily research pro-
grams) and commercial organizations, aimed at prenatal
and nonprenatal populations in the United States and
in the United Kingdom, are described and compared, to
assess their presentation of information about CF and
reproductive options.
Material and Methods
Material
Twenty-eight pamphlets were collected (see Appen-
dix). Twenty were associated with university programs
or nonprofit organizations, and eight were from com-
mercial laboratories. Nineteen were from the United
States, and nine were from the United Kingdom. Because
only pamphlets from noncommercial organizationswere
explicit about whether they were written for a prenatal
or for a general population, only these were used to
compare prenatal with nonprenatal pamphlets. Ten
pamphlets were designed for prenatal populations, and
10 either were designed for a nonprenatal general pop-
ulation or were nonspecified.
Pamphlets were obtained by contacting the principal
investigators of the CF projects that had published re-
sults or that had presented at national meetings. In the
United States, pamphlets were received from eight of
nine clinical studies. Additional U.S. pamphlets were ob-
tained from two nonprofit organizations and from two
university-affiliated clinical service programs of which
the authors were aware. Commercial laboratory pam-
phlets were obtained from the seven laboratories with
booths at the exhibit hall at The American Society of
Human Genetics annual meetings in the years 1992–94.
In the United Kingdom, pamphlets were obtained from
all six of the studies conducted between 1992–1994,
from the two university-affiliated clinical service pro-
grams, and from the main U.K. commercial laboratory
offering CF testing.
Descriptions of CF
The content of the pamphlets was analyzed for state-
ments that described clinical characteristics of CF, in-
cluding the nature of the disease (e.g., that it is “seri-
ous”), its symptoms, treatment, what life is like for
individuals with CF, and life expectancy for individuals
with CF. Statements that described basic genetics and
the chances of being a carrier or of having a child with
CF were excluded.
Each sentence describing CF was then given a clas-
sification of positive, negative, or neutral. The categor-
ies of positive and negative were used to capture both
the content of the sentence and the sentence’s tone or
“slant” and, hence, the message or image it conveyed
(see table 1).
Sentences that were considered negative included
those that focused on (1) the clinical complications of
the disease, (2) the burden of caring for those with CF,
(3) the shortened life span of those with CF, despite
treatment, and (4) the reduction in the quality of life of
an individual with CF. Sentences that were considered
positive included those that focused on the facts that (1)
treatment can help, (2) those with CF have the ability
to participate in other important life activities, (3) life
with CF is manageable, (4) life expectancy is improving,
and (5) CF does not affect intelligence. We categorized
as neutral those sentences that did not obviously qualify
as positive or as negative.
Interrater reliability between two of the authors, in a
sample of 200 sentences, was 81%. Any rating dis-
agreement was discussed until mutually agreed on, and
ultimately produced a consensus rating for each state-
ment. Of the 38 disagreements in our sample of 200,
14 were disagreements between positive and neutral, of
which 10 (71%) received a revised consensus rating of
neutral and 4 (29%) received a revised rating of positive.
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Figure 1 Examples of messages conveyed by statements about life expectancy
Twenty-four were disagreements between negative and
neutral, of which 17 (71%) received a revised consensus
rating of neutral and 7 (29%) received a revised rating
of negative.
Life Expectancy
Sentences that made reference to the life expectancy
of an individual with CF were analyzed further. These
included sentences about how long an individual with
CF could expect to live and sentences that referred to
changes in life expectancy. Given that a large number
of these sentences were composed of more than one
statement about life expectancy, the unit of analysis was
any statement within any sentence that referred to cur-
rent or future life expectancy. For each pamphlet, the
number of life-expectancy statements was recorded, and
each statement was further classified along three dimen-
sions: (1) whether life expectancy was presented in terms
of descriptive words or in terms of particular numbers;
(2) of those statements using numbers, what ages were
given; and (3) whether the description was presented in
terms of death, survival, or expected life span. In ad-
dition, each pamphlet’s life-expectancy statements were
considered together, to determine whether there was a
dominant tone or message of optimism/hope, pessimism/
caution, or neither (see fig. 1).
Reproductive Options
Statements were included in this category if they men-
tioned any reproductive option after a positive test for
either an individual carrier, a carrier couple, or an in-
dividual or couple whose fetus was affected. A list of
the specific recommendations mentioned in each pam-
phlet, for each of these three groups, was compiled. Fi-
nally, for the group of recommendations made when the
fetus is affected, if the option of abortionwasmentioned,
the words in which this option was expressed were
noted.
Statistical Analysis
Nonparametric statistics were used because of the
small sample size in this study. For descriptions of CF,
comparisons between types of pamphlets were made on
the basis of the median numbers of neutral, positive, and
negative sentences they contained, by Mann-Whitney U-
tests. To control for the number of statements in any
one pamphlet, comparisons were also made on the basis
of ratios of neutral, positive, and negative sentences to
the total number of sentences contained in a pamphlet.
For reproductive options, comparisons were made be-
tween types of pamphlets, by Fisher’s exact test.
Results
Descriptions of CF
The 28 pamphlets contained 297 sentences describing
CF, including 192 neutral, 57 positive, and 48 negative
sentences. The median number of sentences was 6.5,
with a range of 1–37. The numbers of neutral, positive,
and negative sentences in each of the different types of
pamphlets are provided in table 2, in the form of me-
dians, of median ratios to the total number of sentences,
and ranges.
Most of the sentences describing CF were categorized
as neutral, whereas a small number of sentences were
categorized as positive or negative. The numbers of pos-
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Table 2
Descriptions of CF: Sentences Classified as Neutral, Positive, and
Negative
Group and
Classification
Median
(Range)
Median Ratio to
Total No. of
Sentences (Range)
All pamphlets ( ):n  28
Neutral 5.0 (1–29) .68 (.17–1.0)
Positive .5 (0–8) .05 (0–.63)
Negative 1.0 (0–6) .17 (0–.60)
Total 6.5 (1–37)
U.S. pamphlets ( ):n  19
Neutral 5.0 (1–29) .67 (.17–1.0)
Positive 3.0* (1–8) .07* (0–.63)
Negative 2.0 (0–6) .18 (0–.60)
U.K. pamphlets ( ):n  9
Neutral 5.0 (2–8) .80 (.4–1.0)
Positive .0* (0–1) .00* (0–.10)
Negative 1.0 (0–3) .14 (0–.60)
* .P ! .005
Table 3
Descriptions of CF in Commercial and Noncommercial Pamphlets:
Sentences Classified as Neutral, Positive, and Negative
Pamphlet Type
and Classification
Median
(Range)
Median Ratio to
Total No. of
Sentences (Range)
Commercial ( ):n  8
Neutral 3.0*** (1–7) .67 (.36–1.0)
Positive .0 (0–5) .00 (0–.46)
Negative 1.0 (0–3) .22 (0–.60)
Noncommercial ( ):n  20
Neutral 6.0*** (1–29) .71 (.17–1.0)
Positive 1.5 (0–8) .15 (0–.63)
Negative 1.5 (0–6) .22 (0–.60)
U.S. commercial ( ):n  7
Neutral 2.0** (1–7) .67 (.36–1.0)
Positive .0* (0–5) .0** (0–.46)
Negative 1.0 (0–3) .25 (0–.6)
U.S. noncommercial ( ):n  12
Neutral 9.0** (1–29) .60 (.17–1.0)
Positive 4.5* (0–8) .23** (0–.63)
Negative 2.5 (0–6) .15 (0–.50)
* .P ! .01
** .P ! .025
*** .P ! .05
itive and neutral sentences were correlated with the total
number of sentences describing CF (Spearman’s r 
and .88, respectively; ). The number of.85 P ! .0001
negative sentences was not significantly associated with
the total number of statements( ; ). Me-r  .31 P  .053
dian ratios were used to control for the contributing
relationship between length of pamphlets and numbers
of positive and neutral statements. Thus, for example,
for the pamphlets as a whole, the median ratio of neutral
statements to all sentences was .68 (i.e., 50% of the
pamphlets have a ratio of neutral to all sentences that
is !.68, and 50% have one that is higher, with a range
of .17–1.0).
United States versus United Kingdom.—Pamphlets
from the United States contained more positive sentences
about CF than did those from the United Kingdom, both
in absolute terms ( ; ) and relative[Z]  2.87 P ! .005
to the number of total sentences in each pamphlet
( ; ). Pamphlets from the UnitedZ  2.91 P ! .005
States and United Kingdom did not differ in length or
in numbers of neutral or negative sentences.
Commercial versus noncommercial.—No differences
between the commercial and noncommercial pamphlets
were observed. Since all but one of the U.K. pamphlets
were noncommercial, however, the inclusion of the U.K.
pamphlets may have minimized the differences. To ad-
dress this, a similar comparison was done on the sample
of U.S. pamphlets only. As shown in table 3, those from
U.S. noncommercial organizations were longer than
those from U.S. commercial organizations ( ;Z  2.37
) and also contained more positive sentencesP ! .025
about CF, both in absolute terms ( ; )Z  2.63 P ! .01
and relative to the total number of sentences in the pam-
phlet ( ; ). Pamphlets from noncom-Z  2.36 P ! .025
mercial organizations also contained more neutral sen-
tences ( ; ); however, this difference didZ  2.04 P ! .05
not persist when median ratios were used to control for
length. ( ; ). There were no other dif-Z  .30 P  .76
ferences observed.
Prenatal versus nonprenatal.—Table 4 shows that,
among the noncommercial pamphlets, those aimed at
prenatal populations contained fewer positive sentences
about CF than were contained in those aimed at non-
pregnant populations ( ; ). No otherZ  2.15 P ! .05
differences between them were observed.
Life Expectancy
There were 49 statements about life expectancy, in 27
pamphlets. Twenty-two of these were in the form of
words (e.g., “some patients die early in childhood”); the
rest provided an age or age range (e.g., “people with CF
generally live for 25 to 30 years”). The ages used to
describe life expectancy ranged from 128 years ( )n  9
to x40 ( ), with seven pamphlets using an agen  4
range of 28–29 and seven using an age range of 30–39.
These statements were variously presented, in terms of
death ( ), survival ( ), and life span or lifen  17 n  19
expectancy ( ).n  13
The pamphlets varied in the messages conveyedwithin
statements about life expectancy, even when using sim-
ilar ages (see fig. 1). Some conveyed an image of a
brighter future for people with CF ( ), whereas oth-n  7
ers presented an image of a shortened life span in spite
of treatment advances ( ). The remaining pam-n  13
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Table 4
Descriptions of CF in Prenatal and Nonprenatal Pamphlets:
Sentences Classified as Neutral, Positive, and Negative
Classification
Median
(Range)
Median Ratio to
Total no. of
Sentences (Range)
Prenatal ( ):n  10
Neutral 4.5 (1–15) .71 (.17–1.00)
Positive .5* (0–3) .05 (0–.33)
Negative 2.0 (0–3) .15 (0–.60)
Nonprenatal ( ):n  10
Neutral 7.0 (2–29) .62 (.35–.86)
Positive 5.0* (0–8) .23 (0–.63)
Negative 1.0 (0–6) .18 (0–.50)
* .P ! .05
Table 5
Frequency of Reproductive Options Presented in CF
Pamphlets
Situation and Option Frequency
One carrier:
Test partner 14
Genetic counseling 11
Test relatives 4
Talk with physician 2
Share information with relatives 1
No further testing 1
Obtain more information 1
Carrier couple:
Prenatal testing 24
Genetic counseling 17
Adoption 2
Gamete donation 2
Have no more children 2
Do not change plans 2
Test child after birth 2
Prepare for child 1
Talk with CF specialist 1
Talk with physician 1
Make decisions about having
children (nonspecific) 1
Affected fetus:
Abortion 15
Continue with pregnancy 9
Early treatment 6
Prepare emotionally 4
Genetic counseling 2
phlets ( ) presented life-expectancy informationn  8
without such images, using phrases such us “the average
life span of a person with CF is approximately 26 years.”
There was no observable pattern between these images
and the various categories of the pamphlets.
Reproductive Options
The frequencies with which different optionswere pre-
sented in the pamphlets are shown in table 5. When one
person was found to be a carrier, the most common
option described was for the individual’s partner to be
tested (14/28). If both partners were found to be carriers,
the majority of pamphlets mentioned the option of pre-
natal testing (24/28). Fifteen mentioned the possibility
of abortion if a fetus was identified as having CF.
Six different terms or expressions were used to refer to
abortion: “termination” ( ), “abortion” ( ),n  8 n  2
“whether to continue the pregnancy” ( ), “choosen  2
not to continue with the pregnancy” ( ), “end then  1
pregnancy” ( ), and “stop the pregnancy” ( ).n  1 n  1
United States versus United Kingdom.—Abortion was
mentioned more often in pamphlets from the United
Kingdom (8/9; ) than in the pamphlets from theP ! .025
United States (7/19). There were no other differences
between these two sets of pamphlets, in the presentation
of reproductive options.
Commercial versus noncommercial.—Abortion and
continuing with an affected pregnancy were mentioned
more often in noncommercial (15/20 and 9/20, respec-
tively) than in commercial pamphlets, in which neither
were ever mentioned ( and , respec-P ! .0005 P ! .05
tively). Among the U.S. pamphlets, abortion was more
frequently mentioned in the noncommercial (7/12) than
in the commercial (0/7) ones ( ).P ! .05
Prenatal versus nonprenatal.—There were no differ-
ences between pamphlets aimed at prenatal populations
and those aimed at general populations in the presen-
tation of reproductive options.
Discussion
Among pamphlets there was wide variation in the
amount and type of information provided about CF.
Much of this variation was in the presentation of positive
information, which was less frequent in pamphlets from
the United Kingdom than in those from the United
States, less frequent in pamphlets from U.S. commercial
laboratories than in those from U.S. noncommercial lab-
oratories, and less frequent in those used in prenatal than
in those used in nonprenatal programs. Information pro-
vided about life expectancy also varied, in the ages used
and, even when similar ages were used, in the general
message conveyed. Statements about life expectancy
seem to reflect two different views of CF. Some empha-
sized that, in spite of treatment, life expectancy is still
reduced, whereas others focused on the fact that life
expectancy is increasing and that the potential exists for
new treatments to extend life expectancy even further.
There are several possible explanations for the vari-
ations among pamphlets. The difference, in positive
statements, between pamphlets from the United States
and from the United Kingdommay reflect different social
attitudes toward disability or the differential influence
of the disabilities rights movement. The less positive in-
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formation in some pamphlets may reflect the pamphlet
authors’ experience with people with CF or with parents
raising a child with CF. For some, this experience may
be limited to an inpatient setting and may not include
exposure to the 65% of individuals with CF who do not
require hospitalization in a given year (Cystic Fibrosis
Foundation 1997). Other pamphlet authors may have a
more negative impression of CF because their experience
is dated and because they are not familiar with the im-
pact of recent improvements. Finally, the profit motive
may also have some influence. Because commercial or-
ganizations earn more when rates of CF testing are
higher, it is plausible that they may minimize positive
descriptions of CF.
Differences in the descriptions of CF may also be re-
lated to different beliefs about the appropriateness of
abortion of fetuses with CF. Although the NIH Consen-
sus Development Conference emphasized that the goal
of providing testing is to allow informed decision mak-
ing, there may be an underlying assumption that people
would or should consider terminating a pregnancy when
the fetus has CF. In this light, the smaller number of
positive statements about CF, in programs designed for
prenatal diagnosis, may suggest that those who develop
such programs are more likely to believe that the abor-
tion of fetuses with CF is appropriate.
In general, it is striking that only half of the pamphlets
mentioned abortion. That abortion was more likely to
be mentioned in U.K. pamphlets perhaps reflects the fact
that abortion is less culturally divisive in the United
Kingdom than in the United States. It is also interesting
that none of the commercial pamphlets from the United
States, which, in terms of providing limited positive in-
formation about CF, were similar to the U.K. pamphlets,
mentioned abortion. Given the volatile nature of the
abortion debate, particularly in the United States, it is
possible that the commercial laboratories were con-
cerned that an explicit discussion might reduce the rate
of CF testing and/or harm their public image. Appre-
hension about abortion is perhaps reflected in the fact,
that, although the term “abortion” is commonly used
in public media, such as newspapers and telephone di-
rectories, only two pamphlets used the term.
The content and style of a pamphlet can send specific
messages about the severity of CF and about the ap-
propriateness of abortion. Such messages may affect
readers’ perceptions of the disease, and, subsequently,
their decisions about testing. Although many of the CF
testing studies assessed peoples’ comprehension of in-
formation, only a few looked specifically at individuals’
understanding of the life expectancy of persons with CF
(Clayton et al. 1995; Bernhardt et al. 1996; Grody et
al. 1997), and none explicitly assessed either pamphlet
readers’ understanding of reproductive options available
to couples with an affected fetus or what life is like for
an affected individual. As a result, it is difficult to assess
how well people understood these issues. Data from
other studies show that the type of information and the
form in which it is presented affect both peoples’ per-
ceptions of a disease and their subsequent decisions
(McNeil et al. 1982; Figueiras et al., in press). It is,
therefore, possible that differences in these pamphlets
could result in different decisions. Variation among the
pamphlets, then, may be one reason for the difference
in the rate of CF carrier testing, which has been docu-
mented across different studies (Marteau and Croyle
1998).
Structural factors in the design of screening programs
also can influence decision making. For example, Tam-
bor et al. (1994) found that neither the perceived severity
of CF nor the likelihood of abortion was associated with
a testing decision, in an HMO population. In the study,
the decision to be tested was influenced by whether the
test could be provided on the same day (23.5% vs.
3.7%). In addition, Bekker et al. (1993) demonstrated
that 70% of people agreed to be tested when a health
professional explained and offered the test on the same
day, but that !10% agreed when they were sent a letter
explaining the test and then were asked to schedule a
separate appointment. Further research is needed to de-
termine how decision making is affected by the rela-
tionship between information provided and the method
by which testing is offered.
There are some limitations to the current study. The
collection of pamphlets was intended to be inclusive and
representative; however, there may have been other pam-
phlets, not available to the authors, that might have
altered the results. We obtained virtually every pamphlet
associated either with a clinical research programorwith
those commercial programs that provided information
at national meetings, but there may have been additional
material, from other nonprofit clinical service programs,
that was not obtained. Recently, Cho et al. (1997) re-
viewed the written material from 179 pamphlets ob-
tained from a U.S. survey of biotechnology companies
and nonprofit organizations (Holtzman and Hilgarnter
1997). Twenty of these were specifically about CF, which
suggests that there are additional U.S. pamphlets that
were not part of our sample. Thus, our category of non-
commercial organizations is most representative of re-
search programs.
Our sample size limits our ability to detect differences,
betwen the various categories of pamphlets, in the state-
ments about life expectancy. For example, we were not
able to detect differences between the pamphlet cate-
gories, in the tone of the statements about life ex-
pectancy.
Another potential shortcoming of our study is that the
designations of descriptive sentences as positive, neutral,
or negative were developed for the current study. Sat-
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isfactory interrater reliability suggests that we were con-
sistent in our approach. In addition, although our sam-
ple size was small, our ability to identify significant
differences demonstrates the magnitude of the differ-
ences among pamphlets.
In the absence of research documenting how varia-
tions in information affect decision making, judgments
will need to bemade, by those running CF carrier–testing
programs, about how best to present information about
CF. What constitutes balanced information? There are
two possibilities, given the rating system used in this
study. One is a pamphlet that uses only neutral state-
ments. Another possibility is a pamphlet containing
some relatively equitable proportion of positive and neg-
ative statements alongside its neutral ones. There is no
a priori answer to how the term “balanced” should be
understood. We advocate the latter type of pamphlet
because we believe that presenting a broad range of in-
formation—some positive, some negative, some neu-
tral—is more consistent with the goal of facilitating au-
tonomous decision making, because it helps individuals
to relate their values, in a meaningful way, to the options
presented.
Because most of the variation found in this study was
in the provision of positive statements, we suggest that
pamphlets should include sufficient positive statements
to achieve balance with the neutral and negative ones.
We are using “balanced” not in a strictly quantitative
sense but, instead, to describe a qualitative breadth in
the tone of information provided. This sense of balance
captures an important aspect of the relationship between
the provision of information and autonomous decision
making.
The results of the present study lead to some prelim-
inary conclusions. First, the wide variability of infor-
mation about CF and reproductive options suggests that
current pamphlets do not seem to meet the NIH rec-
ommendation for balanced information to afford indi-
viduals the opportunity to make autonomous decisions.
Second, researchers must consider the role that written
material may play in affecting the results obtained from
screening programs for CF. Third, additional research is
needed to delineate more fully the impact that infor-
mation has on decisions. Fourth, in the absence of these
data, those preparing educational material should ap-
preciate that they are making choices about what in-
formation to exclude, what information to include, and
the message conveyed.
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Appendix
Table A1
Pamphlet Characteristics
Pamphlet Type
and Institution Reference(s)
U.S. noncommercial:
Baylor University
Johns Hopkins University Tambor et al. (1994),
Bernhardt et al. (1996)
Macro International
Michigan State University
National Society of Genetic
Counselors
Vanderbilt University Clayton et al. (1995, 1996)
University of North Carolina Sorenson et al. (1997)
U.S. noncommercial (prenatal):
Foundation for Blood
Research
Doherty et al. (1996)
Kaiser Permanente Witt et al. (1996)
UCLA Grody et al. (1997)
University of Pennsylvania
University of Rochester Loader et al. (1996)
U.S. commercial:
Collaborative Research
Genetics and IVF Institute
Integrated Genetics
MediGene
Nichols Institute
SmithKline Beecham
Vivigen
U.K. noncommercial:
Guy’s Hospital, London Bekker et al. (1993, 1994),
Axworthy et al. (1996)
St. Mary’s Hospital, London Watson et al. (1992)
University of Wales Payne et al. (1997)
U.K. noncommercial (prenatal):
University of Aberdeen Miedzybrodzka et al.
(1995a, 1995b)
University of Edinburgh Mennie et al. (1992,
1993a, 1993b)
University of Leeds
St. Bartholomew’s, London
Wolfson Foundation Genetic
Centre, Manchester
Harris et al. (1993)
U. K. commercial:
University Diagnostics Limited
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